Neuromidine, tablets 20 mg 50 pcs

Neuromidin^® has direct stimulating effect on impulse conduction along the nerve fibers, inter-neuronal and neuromuscular synapses of CNS and peripheral nervous system.

The pharmacological action of Neuromidin^® is based on the combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses.

Neuromidine^® enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.

Neuromidine^® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

– Increases smooth muscle organ contractility under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except potassium chloride;

– improves memory, inhibits the progressive course of dementia.

In preclinical studies Neuromidine^® had no teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects and did not affect the endocrine system.

Indications

Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies.
Diseases of the central nervous system: bulbar palsy and paresis; recovery period of organic lesions of the central nervous system, accompanied by motor and/or cognitive impairment.
Treatment and prevention of intestinal atony.

Pharmacological effect

Cholinesterase inhibitor. It has a direct stimulating effect on the conduction of impulses along nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous systems. The pharmacological action of the drug Neuromidin® is based on a combination of two mechanisms of action: blockade of potassium channels in the membrane of neurons and muscle cells; reversible inhibition of cholinesterase at synapses.
Neuromidin® enhances the effect on smooth muscles of not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.
Neuromidin® has the following pharmacological effects: improves and stimulates impulse conduction in the nervous system and neuromuscular transmission; enhances the contractility of smooth muscle organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; improves memory, inhibits the progressive development of dementia.

Active ingredient

Ipidacrine

Composition

1 ml of the drug contains:
active ingredient: ipidacrine hydrochloride monohydrate (in terms of ipidacrine hydrochloride) 5 mg;
excipients: hydrochloric acid, 1M solution (pH stabilizer) to pH 2.8-4.0, water for injection up to 1.0 ml.

Contraindications

Hypersensitivity to any of the components of the drug, epilepsy, extrapyramidal diseases with hyperkinesis, angina pectoris and severe bradycardia, bronchial asthma, mechanical obstruction of the intestine or urinary tract, vestibular disorders, gastric or duodenal ulcers in the acute stage, pregnancy (the drug increases the tone of the uterus) and lactation. Children under 18 years of age (no systematic data on use).

Side Effects

Not known – hypersensitivity reactions (including allergic dermatitis, anaphylactic shock, asthma, toxic epidermal necrolysis, erythema, urticaria, wheezing, laryngeal edema)
Uncommon – dizziness, headache, drowsiness (in case of high doses)
Common: palpitations, bradycardia
Uncommon – increased bronchial secretion
Rarely – diarrhea, pain in the epigastric region
Uncommon – vomiting
Often – drooling, nausea
Often – increased sweating
Uncommon – allergic skin reactions (itching, rash) (when using high doses)
Uncommon – muscle cramps
Uncommon – weakness (when using high doses)
If side effects occur, reduce the dose or interrupt the drug for a short time (1-2 days)

Interaction

Neuromidin enhances the sedative effect in combination with drugs that depress the central nervous system. The action and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic drugs. In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Neuromidin is used simultaneously with other cholinergic drugs. The risk of developing bradycardia increases if β-blockers were used before starting treatment with Neuromidin. Neuromidin can be used in combination with nootropic drugs. Reduces the inhibitory effect on neuromuscular transmission and conduction of excitation through peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.

Overdose

In case of severe overdose, a “cholinergic crisis” may develop. Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constriction of the pupils, nystagmus, spontaneous bowel movements and urination, vomiting, bradycardia, heart block, arrhythmias, decreased blood pressure, restlessness, anxiety, agitation, fear, ataxia, slurred speech, convulsions, coma, drowsiness and general fatigue. Symptoms may be mild.
Treatment: symptomatic therapy is used, m-anticholinergics are used: atropine, trihexyphenidyl, metacin, etc.

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Olainfarm, Latvia